Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
09926 AKESO-B
RTNominal down44.400 -0.600 (-1.333%)
Others

27/09/2021 10:14

Akeso (09926) drug candidate gets clinical trial approval

[ET Net News Agency, 27 September 2021] Akeso, Inc. (09926) said the company's
self-developed innovative drug candidate, IL-4R monoclonal antibody (research and
development code: AK120), was approved and agreed by the Food and Drug Administration of
the United States to initiate a global phase II clinical study for the treatment of
moderate-to-severe atopic dermatitis.
This is a multi-centre, randomized, double-blind, placebo-controlled, parallel, dosage
exploration phase II clinical trial to evaluate the efficacy and safety of AK120 in adult
subjects with moderate-to-severe atopic dermatitis.
AK120 is a novel drug targeting IL-4R of autoimmune treatment diseases independently
developed by the company. AK120 is intended to be used for the treatment of atopic
dermatitis, asthma and other allergic diseases. AK120 clinically treats allergic
autoimmune diseases by blocking the biological activities of dual cytokines IL-4 and
IL-13. (RC)

Remark: Real time quote last updated: 03/12/2021 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.